Estrogen Receptor Positive Breast Cancer - tamoxifen - APBB1 expression

Association details:

Biomarker:	APBB1 expression
Cancer:	Estrogen Receptor Positive Breast Cancer
Drug:	tamoxifen (Estrogen receptor antagonist)
Direction:	Resistant

Evidence:

Evidence Level:

Resistant: C3 – Early Trials

Source:

Pathol Res Pract

Title:

FE65 defines the efficacy of tamoxifen treatment via osteopontin expression in estrogen receptor-positive breast cancer

Published date:

04/15/2022

Excerpt:

FE65 immunoreactivity was significantly associated with higher pathological N factor of the cases examined, and a potential correlation with tamoxifen resistance of the ER-positive patients....In addition, results suggested the clinical value of FE65 as potential prognostic factor and surrogate marker of TAM therapy in ER-positive breast cancer patients.

DOI:

10.1016/j.prp.2022.153898